Allison M Kehlmann (Allison Kehlmann)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 2

Top Topics

Patient Reported Outcomes

Top Venues

JCO oncology practice

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Sienna M Durbin, Debra M Lundquist, Andrea Pelletier, Rachel B Jimenez, Laura A Petrillo, Janice S Kim, Kaitlyn Lynch, Megan Healy, Andrew E Johnson, Nicholas Ollila, Vaishnavi Yalala, Benjamin Malowitz, Allison M Kehlmann, Nicholas Chevalier, Victoria Turbini, Viola Bame, Hope Heldreth, Jenipher Silva, Casandra McIntyre, Dejan Juric, Ryan David Nipp
Time Toxicity Experienced by Early-Phase Cancer Clinical Trial Participants. JCO oncology practice (2024)
Andreas Varkaris, Ferran Fece de la Cruz, Elizabeth E Martin, Bryanna L Norden, Nicholas Chevalier, Allison M Kehlmann, Ignaty Leshchiner, Haley Barnes, Sara Ehnstrom, Anastasia-Maria Stavridi, Xin Yuan, Janice S Kim, Haley Ellis, Alkistis Papatheodoridi, Hakan Gunaydin, Brian P Danysh, Laxmi Parida, Ioannis Sanidas, Yongli Ji, Kayao Lau, Gerburg M Wulf, Aditya Bardia, Laura M Spring, Steven Jay Isakoff, Jochen K Lennerz, Levi Pierce, Ermira Pazolli, Gad A Getz, Ryan B Corcoran, Dejan Juric
Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. Cancer discovery (2023)